Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07078682 · ClinicalTrials.gov registry record · NA

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

A NA study of Uterine Fibroids and Leiomyoma, sponsored by Zenchi.

Recruiting
Registry status
NA
Development phase
42
Enrollment target
1
Study location

NCT07078682 is a NA study of Uterine Fibroids and Leiomyoma that is actively recruiting participants, run by Zenchi. The registered enrollment target is 42 participants, below the 240-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07078682, a NA study of Uterine Fibroids and Leiomyoma, is actively recruiting participants, sponsored by Zenchi.

RECRUITING
Registry status
NA
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.

Interventions

  • DIETARY_SUPPLEMENT Elix Daily Harmony

Study Locations (1)

Nevada

  • Citruslabs - Las Vegas

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2025-08-01
Est. Completion 2026-01
Phase NA

Sponsor

Zenchi

3 total trials

What the Registry Record Tells You About NCT07078682

The ClinicalTrials.gov registry entry for NCT07078682 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (82% lower). The listed sponsor is Zenchi, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Uterine Fibroids appearing as the primary indexed condition, and to 1 intervention - of which Elix Daily Harmony is the first listed.

NCT07078682 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT07078682 about?

NCT07078682 is a clinical study titled "An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms". This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validat...

What is the current status of trial NCT07078682?

This trial is currently recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2025-08-01. Estimated completion is 2026-01.

What conditions does trial NCT07078682 study?

This clinical trial studies the following conditions: Uterine Fibroids, Leiomyoma, Menstrual Pain.

What interventions are being tested in trial NCT07078682?

The interventions under investigation include: Elix Daily Harmony (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07078682?

This trial is sponsored by Zenchi, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07078682 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Fibroids

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.